Supply chain middlemen ‘pocket half of US branded medicine spending’
pharmaphorum
JANUARY 13, 2022
Over the same period, total gross expenditures on brand and generic medicines nearly doubled – from $268 billion to $517 billion, according to the report. Growth in spending on branded medicines was driven “primarily by increases in payers’ statutory and negotiated rebates and fees,” it says.
Let's personalize your content